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Including the true tissue kallikrein KLK1, kallikrein-related peptidases (KLKs) represent a family of ﬁfteen
mammalian serine proteases. While the physiological roles of several KLKs have been at least partially
elucidated, their activation and regulation remain largely unclear. This obscurity may be related to the fact
that a given KLK fulﬁlls many different tasks in diverse fetal and adult tissues, and consequently, the
timescale of some of their physiological actions varies signiﬁcantly. To date, a variety of endogenous
inhibitors that target distinct KLKs have been identiﬁed. Among them are the attenuating Zn2þ ions,
active site-directed proteinaceous inhibitors, such as serpins and the Kazal-type inhibitors, or the huge,
unspeciﬁc compartment forming a2-macroglobulin. Failure of these inhibitory systems can lead to certain
pathophysiological conditions. One of the most prominent examples is the Netherton syndrome, which is
caused by dysfunctional domains of the Kazal-type inhibitor LEKTI-1 which fail to appropriately regulate
KLKs in the skin. Small synthetic inhibitory compounds and natural polypeptidic exogenous inhibitors
have been widely employed to characterize the activity and substrate speciﬁcity of KLKs and to further
investigate their structures and biophysical properties. Overall, this knowledge leads not only to a better
understanding of the physiological tasks of KLKs, but is also a strong fundament for the synthesis of small
compound drugs and engineered biomolecules for pharmaceutical approaches. In several types of cancer,
KLKs have been found to be overexpressed, whichmakes them clinically relevant biomarkers for prognosis
and monitoring. Thus, down regulation of excessive KLK activity in cancer and in skin diseases by small
inhibitor compounds may represent attractive therapeutical approaches.
 2010 Elsevier Masson SAS. Open access under CC BY-NC-ND license.1. Introduction
Regulation of protease activity in the living organism is a highly
complex task that involves all levels of cellular organization. Control
and timing of protease activity starts with gene expression, tran-
scription and translation, and continues with protein targeting
and zymogen activation. Once activated, the protease is often kept
in check by endogenous inhibitors, while the last steps of protease
regulation may be limited proteolysis and ﬁnal degradation. The
emerging research in the ﬁeld of tissue kallikrein-related pepti-
dases (KLKs) provides many diverse examples for nearly all aspects
of protease regulation by inhibitors.
Tissue kallikrein (Kallikrein 1, KLK1) and the kallikrein-related
peptidases are (chymo)trypsin-like serine proteases, belonging to
family S1A of clan PA(S) according to the MEROPS classiﬁcation [1].
Prior to the introduction of a new nomenclature in 2006, the KLKs
were often referred to as hKs or rKs for human and rat proteins,
respectively [2]. Fully sequenced genomes of placental mammals,fax: þ43 662 8044 7209.
).
nder CC BY-NC-ND license.such as primates or rodents, and even of marsupials (e.g. the
opossum), exhibit at least eleven KLK genes, but usually lack the
counterparts of human KLK2 andKLK3 [3,4]. However, the numbers of
corresponding proteases vary from ten KLKs in cows, eleven in dogs,
and 26 ones in mice. The latter possess a series of functional KLK1
paralogs [2,5,6]. Kallikrein 1 and the kallikrein-related peptidase
genes are organized in a single cluster on chromosome locus 19q13.4
[7,8]. The15 humanKLKmembers are only distantly related to plasma
kallikrein, which shares 38% identical residues with KLK1 in the
catalytic domain, while KLK1 and trypsin share 46% identity [9,10].
One or more KLK genes are expressed in nearly all tissues
and ﬂuids of the human body. They fulﬁll a diverse range of tasks
throughout one’s lifetime from embryonic development to processes
in adulthood [8,11e13]. KLKs are intracellulary synthesized as
precursors with a signal peptide (15e34 amino acids) that is cleaved
off upon secretion into the endoplasmatic reticulum. The proform or
zymogen of the KLK protease is extracellularly activated by the
removal of the propeptide (3e37 amino acids), resulting in active
proteases of 223e238 residues (Fig. 1), and in some cases reaching
molecular weights of up to 50 kDa due to heavy glycosylation [14].
The activation process of KLKs may involve autoactivation [15e17],
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bostasis axis, such as plasmin, plasma kallikrein, and factorXa [21], or
the proteolytic activity of other proteases, such as urokinase-type
plasminogen activator (uPA),matrixmetalloproteinases (MMPs), and
dipeptidyl peptidase I [22e24]. However, the KLK activity is not
restricted to regulation by steroid-dependent expression [25e27] or
by ﬁne-tuned zymogen activation. In the case of KLKs 6, 12, and 14,
from example, regulation is likely, at least in part, achieved by
autolysis [17,28e31]. Furthermore, in some cases an interplay of KLKs
and their correspondingnatural inhibitors has been established, even
with pathophysiological signiﬁcance [32]. However, many potential
inhibitors of KLKs have not yet been unambiguously assigned to
a given KLK. Another unusual feature of certain KLKs is the timescale
of their activity, which can reach months, if not years, as seen with
KLK4 in tooth development, which was also observed in a compar-
ison of Klk4/lacZ knockin mice and the wild type [33,34].
Overall, the human KLKs can be subdivided into in several
tissue-speciﬁc groups with distinct physiological substrates
and functions. In the 1920s and 1930s, the ﬁrst kallikrein (KLK1)
was discovered and characterized as a proteolytic enzyme, mainly
occurring in urine, kidney, and the pancreas, the latter being the
inspiration for the protein’s name which is derived from the Greek
word for pancreas (kallikr3a2, Kallikreas) [35e37]. A major func-
tion of KLK1 is the reduction of blood pressure by releasing the
peptide hormone Lys-bradykinin (kallidin) from low molecular
weight kininogen, which effects muscle relaxation and inﬂamma-
tory processes [38]. Knockout of the Klk1 gene in mice causes both
cardiovascular abnormalities and a defect of efﬁcient renal tubular
calcium absorption [39,40]. Intriguingly, administration of this
protease can reduce cardiac and renal injuries, restenosis, and
ischemic stroke and promotes angiogenesis and skin wound heal-
ing [41]. Similar to the other “classical” KLKs, KLK 2 and 3, which
were discovered in the late 1980s, KLK1 features an extended
“99-loop” (also called kallikrein loop) of 11 inserted amino residues
with respect to chymotrypsin. Among the “new” KLKs, KLK 4e15
that were gradually characterized from the mid-1990s onwards,
KLKs 8e13 possess 99-loop insertions from two to eight residues
(see alignment in Fig. 1).
In the prostate, KLKs 2, 3, 4,11, and to some extent KLKs 14 and 15,
are produced for secretion into seminal plasma [8,11]. There, they
most likely activate each other in a cascade-like manner resulting in
the degradation of semenogelins and ﬁbronectin, mainly by KLK3
andKLK14, for semen liquefaction [42,43]. Since KLK3 (PSA, “prostate
speciﬁc antigen”) blood plasma levels correlate with prostate cancer
progression, an immunoassay for PSA has become a widespread
medical application, despite its moderate reliability as prognostic
biomarker formalignant processes. Thus, there still remains the need
for additional speciﬁc KLK tumor markers [44e46]. One of these
promising markers is KLK4, which is distinctly expressed in the early
stages of prostate cancer [47]. Interestingly, KLK4 has the capacity to
activate the proform of the urokinase-type plasminogen activator
(pro-uPA) and to modulate the activity of its receptor uPAR, both of
which play a signiﬁcant role inprostate and ovarian cancer [48,49]. In
addition, KLKs 2, 4, 5, 6, and 14 seem to be potential players in signal
transduction via activation of G-coupled protease receptors, such
as PARs 1, 2, and 4, resulting, e.g. in inﬂammation or in tumor cell
proliferation and migration [50e56].
In addition to its role in the prostate, which is not yet fully
understood, KLK4 is imperative for tooth development, particularly
in formation of enamel, which also depends on MMP-20 [57].
Under normal circumstances, both proteases degrade the extra-
cellular matrix required for the growth of dentin crystallites. Single
mutations, however, result in either the malfunctioning of MMP-20
or KLK4, causing the hereditary disease amelogenesis imperfecta,
which is characterized by very fragile teeth [58,59]. Morespeciﬁcally, KLK4 seems to be crucial for the formation of large
coherent enamel crystallites, as seen in Klk4 knockout mice [34].
A larger subset of kallikrein-related peptidases, namely KLKs 5, 7,
11, and 14, is highly expressed in human skin, mainly in the outer-
most layer, the stratum corneum, while KLKs 6, 8, 10, and 13 are
found at medium expression levels [11,13,60]. KLKs 5, 7, and 14 are
capable of degrading proteins of the corneodesmosomes, leading
to desquamation, the shedding of corniﬁed skin cells [61e63]. In
contrast, KLK8 is involved in cellular differentiation and healing of
the skin [64], similar to KLK6, which induced rapid wound healing
by promoting keratinocyte proliferation and migration in a mouse
model based on the shedding of E-cadherin by Klk6 [65]. Also, KLKs
4, 5, and 8 speciﬁcally activate themetalloproteinases meprin a and/
or b, which are located in separate layers of the epidermis [66]. Tight
activity regulation of these KLKs by several types of inhibitors is
necessary, otherwise diverse skin diseases will develop [67].
Intriguingly, two KLKs, KLK6 and KLK8 (also termed neurosin
and neuropsin, respectively), are expressed at higher levels in
human brain [8,68]. KLK6 accumulates at brain lesions of humans
and investigations in mice suggest that excessive KLK6 activity
causes inﬂammation of the central nervous system and promotes
multiple sclerosis through demyelinating activity [69,70]. The
physiological role of KLK6 seems to be both de- and remyelination
of glia cells, contributing to neurite and axon growth after injuries
[71]. In contrast, KLK8, which mostly occurs in the hippocampus, is
involved in long term potentiation (LTP) andmemory acquisition by
restructuring synapses, as shown by mouse models [72e75].
Furthermore, in human brains with Alzheimer’s disease amore than
10-fold expression of KLK8 was observed [76]. On the other hand,
Klk8 knockout mice were shown to be susceptible to epileptic
seizure [77]. Furthermore, single nucleotide polymorphisms in the
human KLK8 gene are associated with manic-depressive disorder
and cognitive impairment [78].
Although the KLK9 protease is present in many tissues and
dominates among all KLKs in fetal and adult heart [11], no physi-
ological function has been deﬁned so far, however, it may serve as
an ovarian and breast cancer marker [79]. Similarly, KLKs 10, 12, 13
and 15 are associated with distinct cancers without established
(patho)physiological roles [17,80,81]. Nevertheless, there are some
indications of a tumor suppressor role for KLK10 in breast cancer
[82], KLK12 may be involved in angiogenesis regulation [83], KLK13
in ovary tissue remodelling and interleukin processing [84,85], and
KLK15 in KLK3/PSA activation [86]. Intriguingly, expression of KLKs
in the female reproductive system appears to be complementary to
the expression pattern of KLKs in prostate, suggesting an activation
cascade that probably involves all KLKs during impregnation [87].
As we will see later for the KLKs, natural inhibitors of proteases
often bind directly to the active site, exploiting some degree of
complementarity at the interaction surface [88e90]. Expectedly, the
more the components of the inhibitor bind to distinct speciﬁcity
pockets of the protease, the more speciﬁcity and afﬁnity can be
gained for inhibition [91], which in some cases may be enhanced by
additional binding of the inhibitor to so-called exosites [92e94]. Also,
knowledge of the substrate speciﬁcity of the KLKs will be a guideline
for the identiﬁcation of endogenous (and perhaps exogenous)
inhibitors, and for the design of synthetic substrates, as well as of
highly speciﬁc inhibitors, which may eventually yield powerful
pharmaceutical compounds. Numerous studies have investigated the
speciﬁcity for all KLKs, using either individual chromogenic and ﬂu-
orogenic substrates, such as in the case of KLKs 8,12,15 [17,95e97] or
systematic positional scanning approaches for KLKs 3, 4, 5, 6, 7,10,11,
13, 14 [98e101], phage display for KLKs 1, 2, 3, 4, 6, 14 [102e107], or
peptide libraries for KLKs 1, 2, and 3 [108e110]. In addition, KLK
cleavage sites in natural substrates have also been analyzed to a large
extent. Since these studies show many differences, sometimes stark
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Table 1
Statistical speciﬁcity patterns of human KLK peptidases cleavage sites, according to MEROPS speciﬁcity matrices for peptide residue positions P4 to P40 that bind to protease
subsites S4 to S40 with the scissile bond between P1eP10 (SchechtereBerger nomenclature [306]). In cases without established matrix, the information on natural and
synthetic substrates was used to derive a score from the incidence of a residue, whereby the P1 value was always set to 100%. The font size corresponds to the frequency of
a residue in published KLK substrates (an incidence cutoff was individually chosen, in order to limit the number of residues at a given position). Hydrophobic residues are
depicted in black, polar ones in green, acidic ones in red, and basic ones in blue. For KLK9 only data of one substrate of the rat ortholog (rKLK9) were available [112], while for
KLKs 10, 11, and 13, results from substrate proﬁling studies [99,100,307] have been treated as one substrate per study, employing only the top ranked residues in positions P4 to
P1. For KLK12 published substrates from two studies were analyzed [17,96]. The primary tryptic speciﬁcity for Arg and Lys in P1 of many KLKs is conferred by an Asp189 at the
bottom of the S1 pocket, which is replaced by a Glu189 in KLK15. The three chymotryptic KLKs with a preference for P1-Tyr, -Phe, or -Gln possess a Ser189 (KLK3), an Asn189
(KLK7), and a Gly189 (KLK9), but rat KLK that shares 40% identical residues with KLK9 (61% homology) exhibits an Asp189, although it has a tendency to cleave chymotryptic
substrates. Apparently, KLK1 has a mixed tryptic/chymotryptic speciﬁcity, as was also observed for KLKs 10 and 11 [99].
KLK P4 P3 P2 P1 P1′ P2′ P3′ P4′
KLK1 ASE PAS LFS YR SR ATR G AR
KLK2 GTE GSTQR GLFSTR R LMS GPAS GS GST
KLK3 ISQR SQK VLYQH YQH ST GVS SNQ TE
KLK4 VIF VYE GPLFYS YKR GIS GR GD G
KLK5 GPLD GF GPFS GKR GIS LIS GPS GP
KLK6 PAS GASK GPVLFS
KR GMSN AVLSD GLIS GLWT
KLK7 G GAKR PLFD FYR L R SK K
KLK8 AT GVLDEE GPLR
KR A A V Y
rKLK9 C I P Y Y L D C
KLK10 M E LFD
(M)R
KLK11 M PE LFR MR
KLK12 PVFQD PALFS
KR
KLK13 vYE AYR ALR KR S P T H
KLK14 PT GVL GPS
KR GS VLSD T GP
KLK15 I PLE GFS R I V G G
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is given in Table 1 based on the statistical approach of the MEROPS
speciﬁcity matrices (http://merops.sanger.ac.uk/). The primary
speciﬁcity of the kallikrein-related peptidases will allow a basic
classiﬁcation between inhibitors of the twelve tryptic KLKs (1, 2, 4e6,
8,10e15) and of the three chymotryptic KLKs 3, 7, and presumably 9.
The speciﬁcity of KLK9 remains still unclear, as it cleaved P1 Arg
containing pro-KLKs at very slow rates [20], while enzymatic data are
only available for the rat ortholog rKLK9 (Table 1) [111,112], which
possesses as major determinant of P1 speciﬁcity an Asp189, in
contrast to the unusual Gly189 of human KLK9 (Fig. 1). Furthermore,
the preference of KLKs 1, 10, and 11 appears to be mixed tryptic and
chymotryptic (Table 1) [99]. It should be noted that the proteolytic
activity of recombinant KLK10 is rather slow and only observed inFig. 1. Primary and tertiary structure of KLKs A: Sequence alignment of kallikrein 1 (KLK1) and
Secondary structure is shown for KLK3/KLK5 for b-strands (arrows) and a-helices (cylinders)
The “classical” KLKs 1, 2, and 3 share 61e79% identical residues, while the conservation of t
displayed with a grey background, while residue 16 that is located in the P1, positionwhen the
KLK5 (green) as ribbon representation in stereo. The catalytic triad residues (His57, Asp102, Se
speciﬁcity, respectively, are depicted as stick models, as well as the N-terminal residue 16 with
of the classical KLK3 is depicted in red.vitro with Leu16 as N-terminal residue, followed by three inserted
residues (Fig. 1) [20]. In addition to a problematic KLK10 activation in
vivo at Glu16C, if tryptic or chymotryptic proteases were the activa-
tors, KLK10 exhibits a Ser193 instead of the extremely conserved
Gly193 (Fig. 1). A Ser193 might affect the oxyanion pocket function,
similar to various factor XIa mutants of residue 193 with reduced
activity and inhibitor binding capacity [113]. Nevertheless, in addi-
tion to the proof of enzymatic activity of recombinantly expressed
KLK10, it was demonstrated that native KLK10 from human ovarian
ascites ﬂuid is associated with two endogenous protease inhibitors
and reacts with an activity-based probe [114].
Fine tuning of any protease inhibitor interaction depends on
characteristic structural features, including electrostatics, ﬂexi-
bility, and exosites on protein surfaces, which will be investigatedthe human kallikrein-related peptidases KLKs 2e15 with bovine chymotrypsin (bCTRA).
. Propeptides are included and the numbering is derived from chymotrypsinogen [247].
he “new” KLKs 4e15 ranges from 38% to 57% [130,300]. Highly conserved residues are
propeptide is cleaved off is shownwith blue background. B: Overlay of KLK3 (beige) and
r195), and Ser189 of KLK3 and Asp189 of KLK5, which determine chymotryptic or tryptic
Asp194 that form a salt bridge, thereby stabilizing the active site [301]. The long 99 loop
P. Goettig et al. / Biochimie 92 (2010) 1546e15671550in the following together with the most relevant biological,
biochemical, and pharmaceutical aspects of KLK inhibition.
2. Natural endogenous KLK inhibitors
To date, a great variety of endogenous inhibitors with physio-
logical signiﬁcance in the activity regulation of mammalian kalli-
krein-related peptidases are known. They range from single metal
ions to large protein complexes of more than 700 kDa. In fact, natural
exogenous inhibitors are widely used for scientiﬁc and pharmaceu-
tical studies (see Sections 3 and 4.). In general, nature employs
the following basic principles of protease inhibition: attenuation
by reversible binding of inhibitors, “KO” inhibition by irreversible
binding to the inhibitory molecule, which often involves the forma-
tion of covalent bonds, and compartmentalization. The latter prin-
ciple may be achieved by restricted tissue or organelle localization
of the enzyme or inhibitor; by homo-oligomerization of the protease
itself, which reduces the accessibility to the active site; or by
compartment formation of large inhibitors that internalize proteases,
for which some rare, but biologically signiﬁcant examples exist.
2.1. Inhibition of KLKs by metal ions
The activity of several serine proteases is regulated by endoge-
nous cations. Interestingly, alkali and earth alkali ions rather stim-
ulate protease activity at distinct binding sites, as seen for the
prominent examples of Naþ with thrombin [115e117] or Ca2þ with
trypsin [118,119]. Also, for KLKs 1, 3, 4, 6 and 8 activity stimulation by
Ca2þ, Mg2þ, or Naþ and Kþ ions has been observed [107,120e123].Table 2
KLK afﬁnity matrix for the most relevant endogenous inhibitors. Data for KLKs 9, 10, and
values that are roughly the doubled Ki (B no inhibition,C mM,CC nM,CCC pM rang
103 M1 s1CC), otherwise it was chosen according to the description of the respective p
remains active against small molecule substrates, while protein substrates cannot be cle
KLK Zn2þ a1-AT a1-ACT ATIII a2-AP
KLK1 B C
[171]
B
[196]
B
[196]
KLK2 C
(3 mM)*
[129]
B
[172, 309]
C
[205], [172]
CCC
(þheparin)
[187, 309]
CCC
[172, 309]
KLK3 C
(24 mM)
[134]
CC
[175, 176]
CCC
[232], [176]
C
[187]
KLK4 C
(15 mM)*
[137]
CCC
[178]
B
[178]
C
[178]
CC
[178]
KLK5 C
(4 mM)
[15, 144]
B/C
[173], [170]
B
[173]
B
[173], [170]
CCC
[173], [170]
KLK6 B C
[174]
C
[182]
CC
[174]
C
[174]
KLK7 C
(10 mM)
[147]
CCC
[170]
CCC
[170]
B
[170]
CC
[170]
KLK8 C
(3.3 mM)
[123]
B
[170]
B
[170]
C
[170]
CC
[170]
KLK11 B
[307]
B
[307]
B
[307]
B
[307]
KLK12 C
(10 mM)*
[17]
C/CC
[17], [170]
B
[170]
C
[17], [170]
CCC
[17]
KLK13 B
[170]
B
[170]
C
[170]
CC
[170]
KLK14 C
(2 mM)
[15, 31]
CC
(162 nM)
[63], [170]
C
(5.6 mm)
[63]
CC
(198 nM)
[63]
CC (130 nM
[63], [170]Zn2þ is a metal ion with manifold functions in living organisms and
is present in about 300 human enzymes [124,125]. It may play a dual
role in activity regulation, as it can stimulate serine proteases, e.g.
factor XII [126], and inhibit other ones, such as factor VIIa or
uPA [127,128]. To date, Zn2þ inhibition as a signiﬁcant regulatory
mechanism for KLKs can only be excluded for the intensively
studied KLK1 and KLK6, while KLKs 9e11, 13, and 15 still require
further inhibition studies. Strikingly, for KLKs 2, 3, 4, 5, 7, 8, 12 and
14, inhibition by Zn2þ in the low mM range has been repeatedly
reported (Table 2). Thus, Zn2þ should be considered as “attenuator”
of KLK activity, which binds in a reversible manner to the targets for
ﬁne tuning of their proteolytic action.
2.1.1. Inhibition of prostatic KLKs 2, 3, and 4 by Zn2þ
Human kallikrein-related peptidase 2, also known as glandular
kallikrein 2 (KLK2), is a tryptic protease. While recombinant KLK2
was inhibited by various serpins in the picomolar range, Zn2þ
attenuated its activity against ﬂuorogenic substrates, e.g. Pro-Phe-
Arg-AMC, with a Ki of 3 mM [129]. Lovgren and coworkers describe
the inhibition mechanism as a mixture of competitive and non-
competitive inhibition, hinting to the binding of more than one
Zn2þ per KLK2 molecule and interference with the substrate
recognition region of KLK2. Based on the high sequence homology
to KLK3 (79% identical residues [130]) and in particular the pres-
ence of the conserved His91, His101, and His233, one can assume
that the Zn2þ inhibition mechanism of KLK2 may be, at least to
some extent, similar to KLK3, which is described in the following.
Zn2þ inhibition of KLK3/PSA, which is mostly activated by KLK2
in seminal ﬂuid, is clearly an important physiological regulatory15 were not available. The rating depended on given inhibition constants Ki or IC50
e), or association constants that were also represented (Kass  105 M1 s1CCC, 
ublication (“strong inhibition”CCC, etc.,C slow inhibition). * IC50 ** the protease
aved anymore.
PCI Kallistatin Other serpins LEKTI-1 a2M**
CC
[308]
CCC
[196]
CCC
[229]
CCC
< 25 pM [129]
CCC
PI-6 [204]
CCC
PAI-1 [205]
CCC
[230]
[231]
CC
[192]
CC
MNEI [203]
CCC
[232]
C
PAI-1
[155]
C
[178]
CCC
[170]
B
[170]
CC
C1I
[170]
CC
[218, 219]
C
[173]
CC
[63]
B
[174]
CCC
[170]
CCC
[170]
CC
[218, 219]
CCC
[170]
B
[170]
CCC
PI-6 [206]
C
[170]
B
[170]
CC
[17]
B
[170]
CC
C1I
[17]
B
[17]
CCC
[170]
C
[170]
CC
PAI-1
[170]
CC
[63]
C
[14]
) CCC
[170]
CC
[170]
C
PAI-1
[63]
CC
[63]
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concentration in the human body is found, reaching up to 9 mM
[131]. A ﬁrst study on the activity of natural KLK3 against a chro-
mogenic substrate, MeO-Suc-Arg-Pro-Tyr-pNA, demonstrated Zn2þ
inhibition with an IC50 of 20 mM (Ki 6 mM), whereby a competitive
inhibition type was found, involving the binding of at least two
Zn2þ [132]. Whereas one group using recombinant KLK3 reported
a Kiapp of 45 mM for Zn2þ with non-competitive inhibition, another
group found for natural KLK3 an IC50 of 24 mM with competitive
inhibition [133,134]. From a modelled homology structure of
human KLK3, a Zn2þ binding site was proposed at His91, His101,
and His233, and as a potential fourth ligand an Asp (95, 97, or 98). It
was assumed that a Zn2þ bound His101 could sufﬁciently distort
the catalytic triad via a shift of Asp102, resulting in decreased
proteolytic activity [135]. Interestingly, in a horse kallikrein 3
(eKLK3) crystal structure an equivalent metal site was occupied by
Zn2þ: the coordinating atoms were Asp91 Od2, His101 Nd1, and
His234 N32 (Fig. 2A) [136]. In human KLK3, that was crystallized
with an antibody required for stabilization of the extended 99 loop
but not containing Zn2þ, the region around the 75-loop exhibited
promising ligands for Zn2þ: His25, His70, His75, Glu21, Glu77
and Asp78 [134]. How Zn2þ binding to these ligands could inﬂuence
the protease activity will be elucidated by the example of KLK4.
Recombinant KLK4 tested with the chromogenic substrate
Z-Phe-Val-Arg-pNA was inhibited by Zn2þ with an IC50 value of
16 mM, although a residual activity of about 25% was still observed
at 1 mM Zn2þ concentration, hinting to a non-competitive or mixed
inhibition type [137]. Intriguingly, in enamel which can only form
properly by KLK4 activity, the zinc content is equivalent to 15 mM,
which would correspond to the observed in vitro inhibition range
[138]. As seen in the crystal structure, KLK4 exhibits a unique metal
binding site in the 75 loop with a short helical segment from Glu74-
Gln76, which allows the Glu77 O3 to adopt an optimal conforma-
tion for Zn2þ binding together with the His25 N32 (Fig. 2B) [137]. In
contrast, the 75 loop of trypsin binds an activity enhancing Ca2þ
through the Glu70 and Glu80 carboxylate groups [118], which are
replaced by Leu70 and Ser80 in KLK4. Three external ligands from
a second KLK4 molecule (Glu74 O3, Asp75 Od, and Gln76 O3)
are additionally coordinating the Zn2þ [137]. Although these
ligands could constitute a secondary Zn2þ inhibition site, the single
mutations His25Ala or Glu77Ala abolish the Zn2þ inhibition of KLK4
completely. Thus, binding of Zn2þ at the 75 loop has a long-range
inhibitory effect on the active site that is probably transmitted
through His25 to the N-terminus, causing disruption of the salt
bridge between Ile16 and Asp194, which is required for a functional
active site conformation (Fig. 2B). This mechanism was conﬁrmed
by a strong increase in the accessibility of the Ile16 a-amino of KLK4
for an acetylating agent in the presence of 70 mM Zn2þ [137]. The
same Zn2þ-dependent phenomenon was previously observed for
the lowactivity form of uncomplexed coagulation factor VIIa (FVIIa)
[139]. Interestingly, a Zn2þ mediated cross-talk between the 75
loop and the active site has been proposed for FVIIa as an expla-
nation for the attenuatory effect on its activity, in particular because
its S1 subsite displays an intrinsic tendency to disorder [127,140].
The physiological signiﬁcance of Zn2þ inhibition of KLKs 2, 3, and
4 is most likely the ﬁnely balanced regulation of activation and
protease activity [81,130,141]. Prostatic ﬂuid contains Zn2þ concen-
trations up to 9 mM, which keeps the prostatic KLKs in an inactive
state [131]. Upon ejaculation, the prostatic ﬂuid mixes with epidid-
ymal ﬂuid containing the spermatozoa and with seminal vesicles,
which are rich in the structural proteins semenogelin I and II (SgI and
II) being responsible for initial sperm immobilization in the seminal
coagulum [142]. However, as both SgI and SgII harbor at least ten
binding sites for Zn2þ, most of the seminal plasma Zn2þ will even-
tually be chelated leading to the activation the prostatic KLKs.Especially KLK3/PSA, as the major SgI and II degrading enzyme, will
then rapidly process these proteins which results in semen lique-
faction and allows the initiation of spermmovement [81,130,141,142].
2.1.2. Inhibition of epidermal KLKs 5, 7 and 14 by Zn2þ
It has been reported that the tryptic KLK5 activity against tri-
peptidyl-AMC substrates is inhibited around 12 nM Zn2þ with 25%
residual activity [143],whereas comparable studies foundan IC50value
of 4 mM and apparent inhibition constants Ki ¼ 8 mM at pH 7.0 and
Ki ¼ 2.0 mM at pH 8.0 [15,144]. Considering the extracellular Zn2þ
concentration of roughly 15 mM in skin, a low nanomolar inhibition
constantwould render its targetproteasevirtually inactive. In contrast,
a micromolar inhibitor or attenuator would allow the modulation of
proteolytic activity in addition to stronger polypeptidic KLK inhibitors
that are also present in the outer layers of the skin (see Section 2.2.2).
The studies by Brattsand et al. and Debela et al. conﬁrmed the
reversibility of the Zn2þ inhibition by addition of either EDTA or Zn2þ-
binding substrates, respectively. A comparison of a Zn2þ-free KLK5
crystal structure (Fig. 2C, left panel)with the Zn2þ-boundKLK5 and rat
kallikrein 2 (rKLK2, tonin) structure can explain the inhibition mech-
anism to a large extent (Fig. 2C) [144,145]. In KLK5, Zn2þ is coordinated
by the His96 Nd1 and the His99 N32 and two water molecules.
TheHis96 side chainhas to rotate bymore than90 from theZn2þ-free
conformation to its position in the Zn2þ coordination sphere, while
the rotation of His99 is less than 20. In the KLK5 Zn2þ structure, the
presenceof the inhibitor leupeptin (not showninFig. 2C,middlepanel)
bound to the catalytic Ser195 and occupying the S2 pocket with a Leu
side chain prevented most likely the formation of a coordination
sphere for Zn2þwith a third ligand, namely His57. This conformation,
representing the fully inhibited KLK, can be seen in the rKLK2 (tonin)
structure, which exhibits the Zn2þ ligands His99, His97 (similarly
positionedas theHis96ofKLK5), andmost signiﬁcantly,His57,which is
relocated from its position in the catalytic triad (Fig. 2C, right panel).
The consequence of a disrupted catalytic triad must be inactivation of
the enzyme. However, substrate binding should be possible in this
inhibited state, due to the largely free S2 subsite, which only has to be
unoccupied for the His57 side chain rotation. Also, the observed non-
competitive Zn2þ inhibition of KLK5 is in good agreement with this
mechanistic model, since Zn2þ does not compete with substrates for
active site binding [144]. Interestingly, the substrate H-Gly-His-Arg-
AMCyielded aKi value of about 20 mMfor Zn2þ,with a residual activity
of 25% even at 100 mM [144]which can be explained by a replacement
of His57 in the Zn2þ coordination sphere with the P2-His N32 or by
a “substrate-assisted catalysis”mechanism. In the ﬁrst case, the His57
of KLK5 would be pushed back into the catalytic triad, in the second
case, the P2-His substrate would transiently reconstitute a functional
catalytic triadandcatalyze itsowncleavage, as in theclassicexampleof
a subtilisin His64Ala mutant [146]. In any case, the employed Phe or
Pro-P2 side chains of other ﬂuorogenic or chromogenic substrates
couldnotplay themechanistic role ofHiswhichhas the capacityeither
to coordinate Zn2þ or to activate the Ser Og nucleophile.
Also, the chymotryptic counterpart of KLK5, KLK7, is inhibited
by Zn2þ (Ki(app) ¼ 10 mM) when measured with tetrapeptidyl-AMC
substrates, and reveals an even stronger inhibition with Cu2þ
(Ki(app)¼ 0.6 mM) [147]. Crystal structures of KLK7without bound ions
(Fig. 2D, left panel) and in complex with Cu2þ revealed direct metal
binding by the His99 N32 and by the Thr96 carbonyl O via hydrogen
bonds to awatermolecule (Fig. 2D, middle panel). Since themutation
His99Ala abolished Zn2þ inhibition of KLK7 activity completely, this
metal binding site must be the structural basis of the attenuating or
inhibitory effect of Zn2þ and Cu2þ [147]. Similar to the coordination of
Zn2þ in rKLK2 the catalytic His57 could constitute a more stable
coordination sphere for the cation [145]. A striking parallel to the
situation inKLK7 is found in a Cu2þ complex structure of theArg96His
mutant of rat trypsinwhich can also be inhibited by Cu2þ (21 mM) and
Fig. 2. Inhibitory metal binding sites in KLK crystal structures as ribbon representation with relevant residues as stick models. Dotted lines indicate hydrogen and coordination
bonds, relevant residues are labelled with numbers. A: The Zn2þ ion (grey sphere) bound to horse KLK3 involves ligands Asp91, His101, and His234. The equivalent residues in
human KLK3 are His91, His101, and His233. Probably, the Zn2þ binding to His101 causes a backbone shift of Asp102, concomitantly distorting the catalytic triad (Ser195, His57, and
Asp102) and resulting in a reduced proteolytic activity. B: In KLK4, the inhibitory Zn2þ site is located far away from the active site, which was conﬁrmed by the single mutations
His25Ala and Glu77Ala. Zn2þ binding to KLK4 effects a disruption of the salt bridge Ile16-Asp194 via His25, thereby destabilizing the active site conformation and abolishing its
functionality. C: Zn2þ binding to the active site of KLK5 and rKLK2 in standard orientation. On the left, the free active site of KLK5 is shownwith both His96 and His99 rotated away
from the S2 pocket. The catalytic triad, consisting of Ser195, His57, and Asp102 is connected by hydrogen bonds. In the middle, a Zn2þ ion (grey sphere) has bound to the ligands
His96 and His99 with coordination bonds. On the right, the catalytic His57 of rKLK2 has relocated from the catalytic triad to become the third Zn2þ ligand, together with His99 and
His97. Most likely, a similar conformation in KLK5 represents the reversible Zn2þ inhibited state. Since the S2 subsite is still accessible for most P2 side chains, the inhibited state
allows binding, but not turnover of substrates, as long as the catalytic triad is disrupted. This mechanistic model is in agreement with the observed non-competitive Zn2þ inhibition
of KLK5. D: Cu2þ binding to the active sites of KLK7 and the rat trypsin mutant Arg96His in standard orientation. On the left, the free active site of KLK7 is depicted with the catalytic
triad connected by hydrogen bonds (dotted lines). In the middle, a Cu2þ ion (orange sphere) has bound to the ligands His99 and Thr96-C¼O via a water molecule (red sphere)
with coordination bonds (dotted lines). On the right, the catalytic His57 of rat trypsin mutant Arg96His has rotated out from the catalytic triad to become the second Cu2þ
ligand, together with the mutated His96. A similar conformation in KLK7 with His99 instead of His96 may represent the reversible Zn2þ/Cu2þ inhibited state. As in KLK5 the S2
subsite is still accessible for P2 side chains, allowing binding, but not cleavage of substrates, as long as the catalytic triad is inactive, which agrees with the non-competitive
Zn2þ inhibition of KLK7.
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His96 and His57 that has rotated out of the catalytic triad, which
explains the inactivation of the enzyme [149]. Most likely, the dis-
rupted catalytic triad with His57 bound to Zn2þ (or Cu2þ) representsthe equivalent inhibited state for KLK7 (Fig. 2D, right panel). Again,
the non-competitive Zn2þ inhibition of KLK7 agrees well with this
structure basedmechanisticmodel, inwhich substrate binding is still
possible, as long as P2 side chains are not too large [147].
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tration in the low nanomolar range is sufﬁcient for inhibition of
KLK14 (IC50 ¼ 12 nM) [31], similar to their ﬁndings on Zn2þ inhi-
bition of KLK5 (IC50 < 12 nM) [143]. However, these values seem to
be problematic in that both proteases would basically never be
active in the tissues or ﬂuids, e.g. the epidermis, where they are
predominantly expressed. Moreover, an earlier study measured an
IC50 of 2 mM for KLK14 [15].
Zn2þmodulated activity of epidermal KLKsmay be highly relevant
under physiological conditions. Because Zn2þ levels in mammalian
epidermis are in the higher micromolar range (50e70 mg/g dry
weight) with the Zn2þ/Ca2þ ratio playing a role in skin maturation
[150,151], this metal ion could be important in the activity regulation
of the KLKs 5, 7 and 14, in addition to their natural polypeptide
inhibitors, the lympho-epithelial Kazal-type inhibitor (LEKTI) (see
Section 2.2.2.). Notably, topical ZnO as contained in the widely used
zinc ointments for skin improves wound healing and re-epithelial-
ization [151], which may be based on reduction of an otherwise
excessive KLK activity. Although copper regulation of proteases is not
established, one should consider this alternative to Zn2þ, in particular
for tissues that contain relatively high Cu2þ ion levels, such as the
brain (0.5 mM), where KLK7 is also expressed [130,152].
2.1.3. Inhibition of KLKs 8, 10, and 12 by Zn2þ
The tissue distribution of the KLKs 8, 10, and 12 is more diverse
than the aforementioned prostatic and epidermal KLK groups.
Nevertheless, it has been demonstrated that KLKs 8 and 12 are
inhibited by Zn2þ as well. For example KLK8, which is thought to
have an important function in the hippocampus of the mammalian
brain, is stimulated by 10 mMCa2þ, but inhibited by 3 mMZn2þ [123].
According to the sequence alignment (Fig. 1) it possesses a His99,
which could coordinate the inhibitingmetal ion together with His57
and a backbone carbonyl, as in KLK7. In the case of KLK10 little is
knownabout activation, natural substrates and regulation, except for
the non-prime speciﬁcity and its relatively slow cleavage of someFig. 3. Reaction of a serine protease shown with the molecular surface with a serpin as r
stranded b-sheet (PDB codes of trypsin from 1OPH and a1-AT from 1QLP) [166,302]. The rea
MichaeliseMenten complex of the protease with serpin corresponding to substrate-like cano
complex that exhibits now a cleaved reactive center loop with an N-terminal P10 residue and
P1 residues to the catalytic Ser195. The activation domain of the protease (black spheres) inc
structures (trypsin and a1-AT, PDB code 1EZX) [165].pro-KLK peptides [20,99]. Since KLK10 possesses a Zn2þ binding site
involving the catalytic triadwith His57 and Asp102, as well as Asp99
in the S2 pocket, it is likely that bound Zn2þ would interfere with
substrate binding and catalysis [107]. Similarly, knowledge of the
physiological functions of KLK12 is scarce, although a systematic
study on its inhibitors showed that its activity against ﬂuorogenic
substrates is attenuated by Zn2þ with an IC50 of 10 mM [17].
2.2. Proteinaceous endogenous KLK inhibitors
To date, the most important proteinaceous endogenous KLK
inhibitors belong to the serpins (MEROPS class I.04), Kazal-type
inhibitors (I.01) and the macroglobulins (I.39) [1]. Only two endog-
enous Kunitz-type inhibitors (I.02) acting on KLKs are known.
The ﬁrst one, bikunin, binds KLK1 in the picomolar range,whichmay
also play an important role in lung function and diseases [153,154],
while bikunin is also associatedwith KLKs 6 and 10 in ovarian cancer
ascites ﬂuid [114]. The second one is an inhibitor of hepatocyte
growth factor activator (HGFA), which is involved in tumor
progression and is itself activated by KLKs 4 and 5, which in turn are
inhibited by the domains of HGFA inhibitory type 1 (HAI-1) [155].
One member of the whey acidic protein (WAP) type inhibitor family
(I.17), the secretory leukocyte peptidase inhibitor (SLPI, also anti-
leukoprotease, ALP) was shown to inhibit KLK7, which appears to be
signiﬁcant in protease regulation during desquamation [156].
2.2.1. Serpins e KLK inhibition in blood and prostate
Serpins (derived from SERine Protease INhibitor) are proteins of
33e46 kDa that account for about 10% of human blood plasma
[157e159]. They occur in all kingdoms of life, inhibit (chymo)trypsin-
like and subtilisin-like serine proteases, as well as cysteine proteases,
and play physiological roles even beyond protease inhibition
[160e162]. In contrast to the substrate-like binding of canonical
protease inhibitors, serpins act via a unique “springe suicide” mech-
anism on their target protease. After cleaving the P1eP10-bond in theibbon representation. Left: Protease and unreacted “virgin” serpin with central four-
ctive loop is depicted as black spheres, the P1 and P10 side chain are labelled. Middle:
nical protease inhibitor interaction (PDB code 1OPH). Right: Covalent serpineprotease
an inserted ﬁfth strand (black) in the central b-sheet that is covalently linked with the
luding a large region of the active site is disordered as seen in several protease zymogen
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residue to the catalytic Ser195, it is then rapidly translocated by about
70 Å to the opposite part of the inhibitor [163,164]. Eventually, this
reaction causes a massive structural disorder in the protease (up to
40%), mainly because all stabilizing interactions that were formed
during enzyme activation are lost now, thus preparing the protease
itself forﬁnal degradation by other proteases (Fig. 3) [165]. Awealth of
mechanistic and structural studies, including several complex struc-
tures, have revealed ﬁne details of various steps in serpin protease
interaction (Fig. 4) [166e169]. Although no serpin-KLK complex
structure is known to date and the physiological connection of KLK
serpin interaction is often unclear, serpins are the best studied KLK
inhibitors [12,25].
At ﬁrst glance it seems surprising, that the serpin a1-antitrypsin
(AAT) fails to inhibit the deﬁnite tryptic KLKs 1, 2, 5, 6, 8, 11, and 13
in vitro, whereas strong inhibition is observed for the chymotryptic
KLK7 with an association constant kass of 3.9  106 M1 s1
(Table 2) [170e175]. However, this inhibition pattern can be
explained by the substrate-like reactive loop of AAT with the scis-
sile bond between P1 Met and P10 Ser that should be preferred by
chymotryptic proteases, albeit with a low reaction rate of KLK3
[175]. The KLK3-AAT complex is found increased in benign forms
of prostate hyperplasia from about 2% to 4% of total KLK3 in serum
[176,177]. Recently, immunological analyses of ovarian cancer
ascites ﬂuid indicated that fractions of KLKs 5, 6, 8, and 10 form
complexes with ATT [114]. Also, AAT strongly inhibits the tryptic
KLKs 4 and 14 and to a lesser degree KLK12 [17,31,170,178].
Contrary to AAT, a1-chymotrypsin (ACT) has been detected in
complex with up to 85% of total KLK3 in blood plasma by immu-
noassays, whereby an increased ratio of free to ACT-complexed KLK3
is correlated with progression of prostate cancer [176,179]. Despite
a signiﬁcant concentration of ACT in seminal plasma, it is not
bound to KLK3, whichwas explained by an interference of Zn2þwith
complex formation [180]. The association constants kass for ACTwith
the chymotryptic KLK3, which seems to obey a slow inhibition
kinetic, and KLK7 were 3.1 103 and 3.9  106 M1 s1, respectivelyFig. 4. Serpin reactive center loop (RCL) inserted into the active site of a serine protease
represented as molecular surface (trypsin and a1-AT, PDB code 1OPH). Canonical
(substrate-like) binding before cleavage of the scissile bond between P1eP10 is mediated
by residues P4 to P10, shown as black stick models. Various serpins exhibit canonical
binding extended to P30 and may overall interact with residues from P6 to P50 [184].[133,170]. In line with the presence of a P1 Leu-P10 Ser scissile bond,
ACT does not or only moderately inhibit the tryptic KLKs 1, 2, 4, 5, 8,
and 11e14 in vitro (Table 2) [31,170,172,173,178,181,182]. Interest-
ingly, analyses of human milk and ascites showed that about 5% of
the tryptic KLK6 are bound to ACT in an ACT-KLK6 complex, which
remains stable after HPLC puriﬁcation [182].
Antithrombin III (AT) is the major inhibitor of ﬁbrin clot
generating thrombin and other coagulation factors in blood plasma,
which is further enhanced by a ternary complex with heparin that
links positively charged exosites of AT and its target protease for
optimal binding [183,184]. The relatively slow AT inhibition seen
for thrombin (kass ¼ 104 M1 s1) is accelerated up to 1000-fold
by heparin [185,186]. A comparable effect of heparin has been
observed for the inhibition of KLK2 by AT, which shows elevated
expression and colocalization with KLK2 in tumor cells [187].
In accordancewith a reactive center containing a P1 Arg-P10 Ser, the
chymotryptic KLK3 and KLK7 are not inhibited by AT [170,187].
Among the tryptic KLKs, only KLK6 and KLK14 are moderately
inhibited by AT, although no heparin was added [31,174].
a2-Antiplasmin (AP), the major inhibitor of the ﬁbrinolytic
plasmin, is unique in that it binds to the zymogen and the mature
protease [188,189]. Whether AP is signiﬁcant for the regulation of
KLKs is an unsolved question. In agreement with the reactive bond
P1-Arg-P10-Met that seems to be designed for tryptic proteases, AP
strongly inhibits KLKs 2, 4, 5, and 12 (kass ¼ 2.2  105 M1 s1) and
moderately inhibits KLKs 7, 8, and 13 [17,31,170,172].
The relatively unspeciﬁc heparin-dependent proteinase C
inhibitor (PCI) inhibits various coagulation factors, and can prob-
ably switch between the P2 Phe-P1 Arg-P10 Ser residues in the
reactive center, so that either Phe or Arg inserts into the S1 pocket
of the protease [190,191]. PCI is a fast binding inhibitor of KLKs 1, 2,
5, 7, 8, 13, 14, and a slow binding inhibitor for KLKs 3, and 12
[17,170,192]. Besides a fourfold increased association constant for
PCI with KLK2 in the presence of heparin (kass ¼ 8.7  105 M1 s1),
an inhibition constant below 25 pM has been described [129]. Since
PCI is present at high molar excess in seminal plasma, roughly 30%
of total KLK2 and to a lower extent KLK3 are complexed with PCI,
which are both implicated in the fertilization process [193e195].
Seemingly, one of the serpins, kallistatin, displays high speci-
ﬁcity for KLKs, being a strong inhibitor of KLK1 and KLK7, while
KLK14 is slowly inhibited [170,196]. In spite of the apparent dual
preference for tryptic and chymotryptic KLKs, it cannot inhibit KLKs
5 and 11e13 [170]. The expression of kallistatin in pancreas and
kidney matches that of KLK1 [197]. Interestingly, the speciﬁcity of
kallistatin for KLK1 is derived from the reactive bond P1 Phe-P10
Ser, since an exchange to P1-Arg results in a twofold higher inhi-
bition of KLK, but also in similar inhibition of various other serine
proteases that are not inhibited by wild type kallistatin [198,199].
Most likely, kallistatin regulates the KLK1 activity, inﬂuencing
blood pressure and angiogenesis, which may also depend on the
heparin binding capacity of kallistatin [200e202].
Inhibition of KLKs 5, 7, 8, 12e14 by the C1 inhibitor was only
moderate in vitro, and may also not be signiﬁcant in vivo, as well as
the KLK3 inhibition by the monocyte/neutrophil elastase inhibitor
(MNEI), which can switch at the reactive center P2 Phe-P1 Cys-P10
Met to Phe as P1 residue for chymotrypsin-like proteases [170,203].
The complex of KLK2 with serpin PI-6 that is associated with tissue
damage, necrosis or neoplasia and the complex with PAI-1
that seems to promote cancer by inactivation of the primary uPA
inhibitor [204,205] are likely to be of physiological relevance in the
prostate. However, serpins may interact with KLKs in other tissues,
as exempliﬁed by the human KLK8 (neuropsin) colocalization in
keratinocytes with its strong inhibitor PI-6 [206] and by the inhibi-
tion of murine KLK8 by the tight binding serine proteinase inhibitor
3, which colocalize in mouse brain [207].
Fig. 5. Kazal-type inhibitor with reactive center loop (RCL) bound to the active site of
a serine protease represented as molecular surface (trypsinogen with pancreatic
secretory inhibitor, PDB code 1TGS). The 15 LEKTI-1 domains are homologous to the
classical Kazal-type inhibitors, but 12 domains may be classiﬁed as subtypes. Canonical
binding is achieved by residues P4 to P20 , shown as grey stick models with spheres.
The bond between P1eP10 is scissile, but cleavage is extremely slow, since the
hydrolysis constant is close to unity and the cleaved bond may reconstituted again
[89]. Speciﬁcity of LEKTI-1 domains for chymotryptic or tryptic KLK targets depends on
the P1 residue, which is in most cases an Arg, but a Gln in the ﬁrst domain.
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Soon after the discovery of the 15 domain, 120 kDa Kazal-type
inhibitor, which was called lympho-epithelial Kazal-type inhibitor
(LEKTI), it was found that mutations in its gene (SPINK5) cause Neth-
erton syndrome. The syndrome is characterized bya severe autosomal
recessive genodermatosis with altered desquamation, impaired kera-
tinization, hair malformation and a skin barrier defect [208,209].
SPINK5 knockout mice feature a Netherton syndrome-like condition,
which is based on the hyperactivity of KLKs 5 and 7 that are not
sufﬁciently controlled by their natural inhibitor, LEKTI-1 [210]. Human
mutations in SPINK5 generate LEKTI-variants that have lost different
C-terminal domains, such as d1-4 or d1-8, which is accompanied by
higher concentrations andactivity levels ofmostepidermalKLKs [211].
Mutations in the SPINK5 gene are also responsible for the widespread
atopic dermatitis,which enhances the susceptibilityof patients to food
allergies and asthma [212e214]. In addition to the elevated degrada-
tion of corneodesmosomes in the stratum corneum, KLK5 causes
atopic dermatitis-like lesions via PAR2-mediated thymic stromal
lymphopoietin expression [215]. An NMR analysis of LEKTI-1 domains
1 and 6 demonstrated that their structures differ from the classical
Kazal-type architecture, especially in the reactive center loops. This
maybe due to the lack of a third disulﬁde bond,which is present in the
classical canonical serineprotease inhibitor scheme.Only twoof the15
LEKTI-1 domains contain three disulﬁde bonds [216]. Nevertheless,
several domains of LEKTI-1 are potent serine protease inhibitors and
function according to the substrate-like canonical binding. Canonical
Kazal-type inhibitors present the scissile bond between P1eP10 to the
protease, however, its cleavage is very slow compared with substrate
turnover, as the hydrolysis constant Khydr is in the range of unity
(Khydr¼ [Inhibitorcleaved]/[Inhibitoruncleaved]¼ 1) and the cleaved bond
may be reconstituted again (Fig. 5) [89,217]. Full length LEKTI-1
containsmostly potential P1 Arg residues, but also a P1 Gln-P10 Asp in
the reactive center loop of the ﬁrst domain that might target chymo-
tryptic proteases, in particular KLK7. This suggestion is supported by
a study on natural truncated versions of LEKTI-1 that usually comprise
the ﬁrst domain and did not fail to inhibit the chymotryptic activity in
the outer layers of skin [211]. Further investigations revealed that
domain 6 alone can inhibit both KLK5 and KLK7 [218]. Recombinant
LEKTI-1 fragments of domains 6e8 and 9e12 inhibited KLK5 with Ki
values between 1.2 and 5.5 nM, while fragment d6-90 (a truncated
domain 9) inhibitedKLK7with aKi of 11nM [219]. Additionally, LEKTI-
1 d1-6, d6-90, and d9-12 inhibited KLK5, KLK6, KLK13, and KLK14with
Ki values in the range of 2e416 nM, while only KLK5 was inhibited by
d12-d15 (Ki ¼ 22 nM) [63].
In cultured keratinocytes and in the epidermis it was demon-
strated that the LEKTI-1 precursor is secreted as several fragments,
of which d5, d6, d8-11, and d9-15 speciﬁcally inhibit KLK 5, 7, and
14, whereby the strongest inhibition was seen for KLK5 with d8-11,
although a shift to acidic pH dissociated the otherwise nearly
irreversible, tight binding complex [32].
Recently, a polypeptide of 85 amino acids, expressed in skin and
encoded by the SPINK9 gene with high homology to LEKTI-1 was
discovered and termed LEKTI-2 [220]. This polypeptide was found
colocalized with KLK5 in the epidermis, which possesses the
unusual reactive bond P1-His-P1-Met and inhibits recombinant
KLK5 (Ki ¼ 65 nM), KLK8, but not KLK7 or 14 [221].
2.2.3. Macroglobulins e large compartments for unspeciﬁc
protease removal
In a classical paper, Barret and Starkey elaborated amechanism for
a2-macroglobulin (a2M) inhibition, a huge protein of 720 kDa thatwas
able to block the proteolytic activity of nearly all proteases. At that time
itwasalsoknownthatana2Minhibitedproteasewasstill activeagainst
small substrates, but no longer cleaved proteins. Thus, it was proposed
that a2M is proteolytically attacked by its target protease in a so-calledbait region, which causes a conformational change in a2M, resulting in
an irreversibly trapped protease [222]. This mechanistic description
has remained valid and has been supported and elaborated on
by structural information from electron microscopy and X-ray crys-
tallography. The structural arrangement of the protease free a2M
comprises two dimers with a large central cavity [223]. Uponprotease
cleavage in the bait sequence P692QLQQYEMHGPEGLRVGFYESDV-
MGRGHARLVHVEEPHT730 andsubsequent thiol estercleavagenear the
central region, two b-strands of a2M untwist to expose the central
cavity to proteases, e.g. to chymotrypsin, ofwhich twomoleculeswere
covalently linked inside the central cavity [224,225]. Since the reactive
internal b-cysteinyl-g-glutamyl-ester of a2M can react with any
exposed Lys side chain on a protein surface, any protease can be trap-
ped, and thus a2Mhas been termed a “panproteinase inhibitor”, which
clears the blood from proteases destined for degradation [226,227].
Typically, the protease is not ﬁxed to a large extent and retains
a considerable ﬂexibility inside the a2M cavity after trapping [228].
The ability of a2M to effectively internalize and trap KLK1 has
been demonstrated in vitro and it was even used as a tool to remove
it from samples, where the KLK1 activity was unwanted [222,229].
However, a2M complex formation with KLKs is of physiological
signiﬁcance, too, as observed for KLK2 in serum of prostate cancer
patients [230,231]. Also, KLK3 forms readily stable complexes with
a2M in blood serum, as well as with the a2M homologue pregnancy
zone protein (PZP), which exhibits some interesting mechanistic
differences to a2M [232,233]. Interestingly, KLKs 4, 5, 6, 12, and
13 were not signiﬁcantly inhibited by a2M [17,101,173,174,178],
although in mouse brain KLK8 (neuropsin) was inhibited by the
a2M homologue murinoglobulin 1 and a novel inhibitor, phos-
phatidyl ethanolamine binding protein (PEBP) [207,234].
2.2.4. Autoinhibition in KLK4 oligomers e an exceptional case?
Compartmentalization within proteinaceous inhibitors as in the
macroglobulins is quite rarely realized, whereas proteases provide
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lase, tricorn protease, or a- and b-tryptases the oligomerization
leads to the formation of an internal cavity or blocking of the active
sites that are not accessible for most potential protein substrates
[235e240]. This compartmentalization represents some kind of
self-inhibition, and can be overcome by activators, which induce
a conformational change or transfer substrates to the active site as
in the 26S proteasome [241].
In this context, recombinant, refolded KLK4 exhibited 700 kDa
oligomers in solution, corresponding, to 24-mers,whichwere hardly
active against chromogenic and ﬂuorogenic substrates [137]. On the
contrary, KLK4 that was refolded in the presence of 2 mM Ca2þ
was only monomeric (ca. 25 kDa) and highly active, resulting even
in autodegradation within a few hours [107]. Also, these studies
revealed that in three known crystal forms KLK4 assembled to
oligomers, consisting of stacked cyclic tetramers or octamers,
respectively, in which the active sites are partially blocked (Fig. 6).
Since binding and turnover of even small tripeptidyl-pNA substrates
is sterically not possible, in particular due to a partially blocked S2
subsite, the tetramers and octamers appear to be self-inhibiting
protease forms with regulatory potential [137].
3. Exogenous and synthetic inhibitors in KLK research
In biochemical and biophysical studies both exogenous natural
inhibitors and synthetic small molecules have been used, mostly toFig. 6. Potential autoinhibitory homocomplexof KLK4withmonomers depicted as alternating p
consisting of cyclic tetramers that assemble to octamers, or even higher oligomers, such as dime
become very narrowat the catalytic centers (labelled AS)with Ser195 shown as green balls. In pa
substrates, not to mention large protein substrates [137].analyze the primary speciﬁcity of the respective kallikrein-related
peptidase and then for reﬁned studies of extended substrate speci-
ﬁcity. This approach can be exempliﬁed bya study onmouse KLK1b27,
in which the enzyme was characterized as chymotryptic serine
protease, according to its inhibition by diisopropylﬂuorophosphate
(DIFP), phenylmethylsulfonyl ﬂuoride (PMSF), and tosyl-phenyl-
chloromethyl ketone (TPCK) and chymostatin, in contrast to the
weaker inhibition by the tryptic enzyme inhibitors tosyllysyl-
chloromethyl ketone (TLCK), leupeptin, antipain, soybean trypsin
inhibitor (SBTI), and aprotinin (bovine pancreatic trypsin inhibitor,
BPTI) [242]. Such knowledge often helps to improve the puriﬁcation of
a KLK by preventing autodegradation. Although the abovementioned
inhibitor molecules are rather unspeciﬁc and bind to a great variety
of proteases, they may serve as starting point for highly speciﬁc
compounds, as in the recent example of an activity-based compound
that was employed for immunoﬂuorimetric measurements of active
KLK6: the compound biotin-(PEG)4-Pro-Lys-diphenylphosphonate
formed a covalent bond to the nucleophilic Ser195 Og [243].
3.1. Small molecules
3.1.1. Sulfonyﬂuorides and diisopropylﬂuorophosphate
as catalytic serine inhibitors
The unspeciﬁc irreversible, but toxic serine protease and
esterase inhibitors PMSF (Pubchem CID 4784, http://pubchem.ncbi.
nlm.nih.gov/) or DIFP (Pubchem CID 5936) and their derivativesurple and orange surface representations. In solution and in crystals KLK4 forms oligomers,
rs and tetramers of octamers. Due to intermolecular contacts, the active site clefts of KLK4
rticular the S1 and S2 subsites are hardly accessible for small chromogenic and ﬂuorogenic
Table 3
Exogenous and non-natural inhibitor afﬁnity matrix. The rating (B no inhibition, etc.) is applied as for Table 2. *TPCK related compounds (see Table 4).
KLK PMSF/AEBSF/DIPF BEN/p-ABA Leupeptin/antipain Chymostatin TLCK/PPACK TPCK SBTI/LBTI BPTI
KLK1 C
[245]
C
[310]
C
[245]
B
[245]
C
[245]
KLK2 C
[129]
C
[129]
CC
[129]
C
[129]
KLK3 C
[42, 175]
B
[42]
B
[42]
C
[249]
B
[42]
B
[42]
B
[42]
B
[42]
KLK4 C
[48, 137]
C
[48]
C
[48]
CC
[48]
KLK5 C
[15, 144]
B
[15]
C
[15]
C
[15]
KLK6 C
[174]
CC
[174]
KLK7 C
[147]*
KLK8 C
[123]
C
[123]
C
[123]
B
[123]
KLK12 C
[17]
B
[17]
C
[17]
KLK14 C
[15]
C
[15]
C
[15]
C
[15]
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non-toxic trypsin-speciﬁc aminoethyl benzenesulfonyl ﬂuoride
(AEBSF, Pubchem CID 1701) [244]. For KLK1, inhibition by PMSF and
for KLK3, reaction with PMSF and AEBSF has been reported
[42,245]. Due to the high toxicity, the volatile DIFP is not used for
puriﬁcation purposes.
3.1.2. Benzamidines as tryptic S1 inhibitors
Both benzamidine (BEN) and its derivative para-amino-
benzamidine (p-ABA) are speciﬁc for tryptic proteases, since they ﬁll
the S1 pocket and usually form a salt bridge between their positively
charged amidino group and the negatively charged Asp189. Due to
a lack of additional interaction with the protease, such as binding to
the oxyanion pocket or to the S2eS4 subsites, inhibition constants of
benzamidine range from high mM tomM. In case of KLK6 63 mMBEN
was required for 20% inhibition, while the inhibitor was applied
at 20mM for crystallization andwaswell deﬁned in the S1 site of the
KLK6 structure [174,246]. Deﬁnitely, BEN and p-ABA are useful tools
in protein puriﬁcation and crystallization of tryptic KLKs, since they
inhibit the proteolytic activity and rigidify the active site, as
corroborated by more than 100 corresponding crystal structures
(Pubchem CIDs 2332 and 1725, http://pubchem.ncbi.nlm.nih.gov/).Table 4
Structures of KLK peptidases with PDB accession codes: pKLK, mKLK, rKLK, eKLK: porcin
leucyl-L-argininal, Suc¼ succinyl, CMK¼ chloromethyl ketone, BPTI¼ bovine pancreatic t
amino-4-(triﬂuoromethyl)-coumarin. ** Structure not deposited. *** Un-published data.
KLK pro apo Inhibitor
KLK1 1SPJ [311] 1HIA [263]
pKLK1 2KAI [312]
2PKA [247]
rKLK2 (tonin) 1TON [145]
KLK3 2ZCH [134] 2ZCK [134]
eKLK 1GVZ [136]
KLK4 2BDH [137]
KLK5 2PSX [144]
2PSY [144]
KLK6 1GVL [313] 1L2E [246]
KLK7 3BSQ [314] 2QXG [147]
2QXH [147]
2QXJ [147]
KLK8 *** [315]
mKLK8 1NPM [316]
mKLK13 1AO5 [317]
KLK b3 1SGF [295]Thus, crystal structures of pKLK1, KLKs 4 and 6 in complex with
benzamidine or para-aminobenzamidine were solved, respectively,
explaining subtle differences of the S1 speciﬁcity determinants
(Tables 3, 4) (Fig. 7A, B, C) [137,246,247].
3.1.3. The aldehydes leupeptin, antipain, chymostatin interact with
the S1 to S4 pockets
Remarkably, higher organisms utilize exclusively ions or poly-
peptides as protease activity attenuators or inhibitors, whereas
microorganisms produce various small molecule inhibitors, which
target host proteases [89]. For example, leupeptin (acetyl-Leu-Leu-
Arginal) and antipain (carboxyphenylethyl-carbamoyl-Arg-Val-
Argininal) are suitable competitive KLK inhibitors that are produced
by Actinobacteria, such as Streptomyces [248]. The aldehyde function
of leupeptin and antipain reacts with Ser and Cys nucleophiles to
a transition state-like inhibited protease complex, which is reversible.
Their P1 Arg is suited to inhibit tryptic KLKs, e.g. KLK2 around 100 mM,
while antipainwas amuch stronger inhibitor of KLK8 (IC50¼ 460 nM)
than leupeptin (IC50 ¼ 66 mM) [123,129]. Also, Leupeptin inhibited
KLK5 at 1.7 to 10 mM and cocrystallized with this protease, whereby
the N-terminal extension occupied the subsites S2eS4 [15,144]
(Fig. 7D). The widely used chymostatin is the counterpart ofe, murine, rat, equine kallikrein-related peptidase. Leupeptin ¼ N-acetyl-L-leucyl-L-
rypsin inhibitor. *Acyl-intermediate, derived frommorpholino-carbonyl-KGISSQY-7-
Ion Small molecule Polypeptide
hirustasin
BPTI
benzamidine
Zn2þ
Mu-KGISSQY- *
Zn2þ [136]**
Zn2þ p-aminobenzamidine
Ac-LLR- (leupeptin)
Zn2þ Ac-LLR- (leupeptin)
benzamidine
AAF-CMK
Suc-AAPF-CMK
Cu2þ Suc-AAPF-CMK
Zn2þ Ac-LLR- (leupeptin)
Zn2þ
Fig. 7. Inhibitory small molecules bound to KLK active sites with important residues depicted as stick models. Hydrogen bonds with a distance shorter than 3.5 Å are shown as grey
dotted lines and relevant residues are labelled with numbers. A: Porcine pKLK1 with benzamidine (BEN) occupying the S1 site. The BEN amidino group binds Asp189 only with one
amino group, but involves the Ser226 Og and the backbone carbonyl O of His217. B: KLK6 binds the two amidino N atoms of benzamidine in the S1-pocket with both Od atoms and
one with the Og of Ser190, as well as with the backbone carbonyl O of Asn217, similar to trypsin [303]. C: The binding mode of para-aminobenzamidine (PABA) to KLK4 is similar to
KLK6, but the Ser190 does not participate in stabilizing the amidino groups of the inhibitor, which is additionally bound at the amino group by Ser195. In addition to Asp189, the
Ser190 Og is enhancing the speciﬁcity of the S1 subsite for P1-Lys residues [304,305]. D: Leupeptin binds with the P1-Arg C covalently to the Ser195 Og of KLK5, while the former
carbonyl O (now rather a eO) is accommodated in the oxyanion hole, formed by the backbone NHs of Ser195 and Gly193. The P1 Arg side chain is stabilized by Asp189 and Ser190.
For clarity, additional hydrogen bonds of the P2-Leu carbonyl O and P1 Arg N3 via a water to Gln192 have been omitted. The relatively small hydrophobic S2 subsite is ﬁlled with the
P2-Leu side chain. While the P3-Leu side chain extends to the solvent, its carbonyl O and amide NH tightly bound to the corresponding atoms of Gly216. The acetyl group of
leupeptin partially occupies the hydrophobic S4 pocket. E: Ala-Ala-Phe-chloromethyl ketone (AAF-CMK) is covalently linked with the P1 methylene group to His57 N3 and via the C
atom to the Ser195 Og of KLK7, whereby the former carbonyl O occupies the oxyanion hole. The P1-Phe side chain is located in the large S1 pocket, but does not interact with the
Asn189 at the bottom of the pocket, which is more suited to bind residues with polar tips, such as Tyr or Gln, while Ala190 contributes to the hydrophobic character of this subsite
[99]. Also, the S2 pocket is rather mixed hydrophobic polar and not completely ﬁlled by the P2 Ala, whereas the P3 Ala extends to the bulk solvent and forms hydrogen bonds from
its backbone C]O and NH to the backbone of Gly216. F: Covalent bonds of Suc-AAPF-CMK to His57 and Ser195 of KLK7, as well as the orientation of the oxyanion and the P1-Phe
side chain are the same as for AAF-CMK (Fig. 7E). The P2 Pro ﬁts equally well as an Ala to the S2 subsite, bordered by His57 and His99 (Fig. 7E). Again, the P3 Ala makes only
backbone interactions with Gly216, but contrary to the AAF-CMK, the P4 Ala occupies to some extent the hydrophobic S4 pocket, with the Trp215 side chain as base and His99 and
Leu175 as borders, while the succinyl group in P5 position has no interaction partner on the KLK7 surface.
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It corresponds largely to a tetrapeptide with a leucyl-phenylalaninal
moiety and reacts with proteases as the above described aldehydes.
Chymostatin inhibitionwas described for the chymotryptic KLK3, but
also for the tryptic KLKs 8 and 14 (IC50 ¼ 8 mM and 30 mM)
[15,123,249].
3.1.4. Chloromethyl ketones
Contrary to reversible binding inhibitors, chloromethyl ketones
(CKs, CMKs) are widely used irreversible cysteine- and serine
protease inhibitors, which, similar to aldehydes, allow the design of
speciﬁc inhibitors for an individual target. For example, such cova-
lent inhibitors are suitable for co-crystallization with proteases, but
often require an iterative process of optimization. For the analysis of
the primary KLK speciﬁcity some standard compounds have been
applied. In case of the tryptic KLKs 1, 4, 8 of tosyl-lysyl chloromethylketone (TLCK) was an efﬁcient inhibitor, as well as D-phenylalanyl-L-
prolyl-L-arginyl chloromethyl ketone (PPACK), which inhibited KLK2
at 5 mM [48,123,129,245]. Surprisingly, the chymotryptic counterpart
tosyl-phenylalanyl chloromethyl ketone (TPCK) does not seem
suitable to inhibit KLK3, whereas KLK7 was successfully crystallized
with Ala-Ala-Phe-CMK and succinyl-Ala-Ala-Pro-Phe-CMK, result-
ing in structures with a resolution up to 1.0 Å (Fig. 7E, F) [147].
3.2. Polypeptidic inhibitors
3.2.1. Kunitz- type trypsin inhibitors
Several canonical substrate-like binding Kunitz-type inhibitors
have been employed in research for the analysis of KLK enzymatic
activity (Table 3) [89]. The most common ones are the soybean
trypsin inhibitor (SBTI, I03.001 according to MEROPS), the lima
bean trypsin/Bowman-Birk inhibitor (LBTI, I12.001, which occurs as
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and aprotinin, the bovine pancreatic trypsin inhibitor (BPTI,
I02.001), which is only found in the genus Bos. Interactions of
proteases and the 181 amino acid SBTI are well understood on
functional and structural level, not least because its reactive P1 Arg-
P10 Ile bond was an early target of bioengineering [250,251]. The
much shorter LBTI comprises 71 residues with a P1 Lys-P10 Ser
reactive bond for trypsin-like and a P1 Leu-P10 Ser for chymo-
trypsin-like proteases, but some related Bowman-Birk inhibitors
possess a second reactive bond with P1 Arg [252,253]. Due to its
anticarcinogenic effects this inhibitor type from plant nutrients
gained much interest in medical sciences [254]. SBTI efﬁciently
inhibited the tryptic KLKs 5 and 14 at an IC50 of 100 nM, while KLK6
required only 16 nM for 82% inhibition and KLK4 about 50 mM for
99% inhibition [15,48,174]. It was also demonstrated that SBTI is
a good inhibitor of rKlk2 or tonin (Ki ¼ 160 nM) and rKlk1-c9
(Ki ¼ 70 nM) [111].
Mature BPTI is 58 residues long and presents a reactive loop with
a scissile P1 Lys-P10 Ala bond to tryptic proteases. The BPTI/bovine
trypsin complex was one of the ﬁrst reﬁned crystal structures andFig. 8. Two complexes of porcine and human KLK1 with the exogenous inhibitors BPTI (Ku
representation, relevant residues as sticks labelled with numbers, and hydrogen bonds as gr
inhibitor in white. B: Closer view of the active pKLK1 site, where only the interacting reac
oxyanion hole, while its Nz-atom is hydrogen bonded to the Thr190 Og and carbonyl O, the
chain) disulﬁde bridge occupies the S2 pocket, while the P3 Pro only forms one hydrogen bo
inhibitors, no interaction of the P4 residue Gly is observed. On the prime side, P10 Ala ﬁts to
subsites. C: KLK1-hirustasin complex depicted with the protease in magenta and the inhibito
are displayed, although canonical binding ends with P10. The P1 Arg of hirustasin is bound th
hydrogen bonded to the Thr190 Og and carbonyl O, the Nh1 binds the carbonyl O of His21
Similar to BPTI, the P2 Cys29-Cys48 disulﬁde bridge is located in the S2 pocket and rigidiﬁes
the P20 Arg a not-substrate-like position, in contrast to the P10 Ile. Typical for canonical P3 an
subsite.revealed, in addition to details of canonical binding, that the Ser195Og
is covalently bound to the tetrahedral C atomof Lys15, representing the
transition state of the cleavage reaction [255,256]. Theseﬁndingswere
consistent with kinetic studies that found for BPTI with trypsin
KHydrolysis ¼ [BPTIcleaved]/[BPTIuncleaved] ¼ 0.33, whereby equilibrium is
reached in about one year [257]. Applications of BPTI are manifold in
laboratories, such as the engineering of its speciﬁcity, or its use in
cardiopulmonary surgery and organ transplantation [258,259].
Astonishingly, the pioneers of kallikrein protease research, Kraut,
Werle, and Frey discovered as early as 1930 that certain extracts of
bovine glands (containing BPTI) inhibited the enzymatic activity of
kallikrein (KLK1) [260]. These seminal studies were later conﬁrmed
and evidencewas found that other tryptic KLKs arewell inhibited by
BPTI, such as KLK 2 (IC50 ¼ 30 mM), rKlk2 (Ki ¼ 76 mM), KLK4 (100%
inhibitionwith 4 mMBPTI), KLK5 (IC50¼ 3 mM), KLK12 (IC50¼ 2 mM),
and KLK14 (IC50¼ 3 mM) [15,17,48,129,245]. Despite its considerable
speciﬁcity for tryptic KLKs, to date, only one kallikrein structure in
complex with BPTI has been solved, demonstrating canonical
inhibitor binding in a transition state-likemanner for porcine pKLK1
(Fig. 8A, B) [247].nitz-type) and hirustasin (antistasin-type), respectively. Proteins are shown as ribbon
ey dotted lines. A: pKLK1-BPTI complex displayed with the protease in purple and the
tive loop residues of BPTI are shown. The P1 Lys is bound with its carbonyl O to the
Ser226 Og and virtually not to the Od1 of Asp189. The P2 Cys14I-Cys38I (I for inhibitor
nd with its carbonyl O to the NH of Gly216. In contrast to many other canonical binding
the S1, pocket, but the P20 Arg exhibits a non-canonical binding around the S2, and S3,
r in white. D: Closer view of the active KLK1 site, where the inhibitor residues P4 to P30
e oxyanion hole and its side chain ﬁlls the S1 pocket largely, whereby the Nh1 atom is
7, whereas the interaction distances with the Od atoms of Asp189 are relatively long.
the reactive loop region together with the P30 Cys33I-Cys50I disulﬁde, which adopts as
d P4 residues, the side chain of His28I extends to the solvent and Val27I occupies the S4
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Although produced by the leech Hirudo medicinalis, the canonical
55 residue inhibitor hirustasin with a reactive P1 Arg-P10 Ile bond
apparently inhibits not blood coagulation, as the thrombin inhibitor
hirudin or other protease inhibitors from leech [261,262]. Moreover,
hirustasin discriminates strongly between KLK1 (Ki ¼ 13 nM) and
plasma kallikrein, which is not inhibited at all [261]. A P2 Cys forming
a disulﬁde characterizes this unusual inhibitor type (I15.001) from
the antistasin family, of which a crystal structure was solved in
complex with KLK1, exhibiting the typical transition state geometry
at the reactive P1-Arg and tight interactions from P4 to P2 with the
corresponding speciﬁcity pockets of the protease (Fig. 8C, D) [263].
4. Pharmaceutical approaches
Most of the small molecule inhibitors that have been employed
in biochemical studies of KLKs are often of insufﬁcient speciﬁcity,
or cannot be administered to patients. Thus, the synthesis of
biotolerable drugs or the engineering of large biomolecules from
natural sources is required. The function of distinct KLKs in certain
diseases is not alwayswell deﬁned, as shown in an overview disease
matrix (Table 5). However, KLKs are attractive diagnostic and
therapeutic targets, particularly the members of the family that are
involved in prostate cancer and skin diseases [264].
4.1. Synthetic small compounds directed against KLK3 and KLK7
In order to maximize bioavailability and efﬁciency some basic
principles should hold true for the compound to be designed. A
famous and successful guideline for small molecule drugs is to obey
Lipinski’s “rule of ﬁve” and its recent modiﬁcations [265e267];
nonetheless, a signiﬁcant part of pharmaceuticals is derived from
natural compoundswhich tend to exceed the initial rule’s suggested
molecular weight of 500 Da [268]. It is also of high importance to
consider the exact time and tissue localization in an organism for
the administration of a given drug, in order to avoid undesirable
side effects [269]. Strategies to obtain optimal drugs usually employTable 5
Disease matrix for human kallikrein-related peptidases. The double dots indicate conﬁrm
KLK is used as a disease marker or acts as a tumor suppressor.
KLK Cancer Skin disease
Prostate Ovarian Breast Netherton
syndrome
Atopic
dermatitis
KLK1
KLK2 C
[25]
KLK3 CC
[25]
C
[25]
KLK4 CC
[47,319]
KLK5 CC
[25,114]
C
[25]
CC
[211]
C
[60]
KLK6 CC
[25,114]
C
[26]
C
[211]
KLK7 CC
[211]
C
[60]
KLK8 CC
[25,114]
C
[26]
C
[211]
C
[60]
KLK10 CC
[25,114]
C
[25]
KLK11 C
[25]
C
[25]
C
[26]
C
[211]
C
[60]
KLK13 C
[25]
C
[211]
KLK14 CC
[31]
C
[25]
C
[211]combinations of 1) massive screening campaigns; 2) “directed
evolution”; 3) “rational design”, often supported by structural data
of biomolecules as well as a more sophisticated multiparameter
design, yielding extremely tight binding serine protease inhibitors
[270e273]. Common features of small molecule serine protease
inhibitors are peptidomimetic groups that bind some of the speci-
ﬁcity pockets and an altered “scissile” bond, which may react with
the catalytic serine, such as those present in phosphonyl, boronic
acid, inverse substrate esters, a-keto heterocycles, isocoumarins,
and succinimide derivatives [274].
The major target among the KLKs for medical and pharmaceu-
tical research is deﬁnitely KLK3/PSA. Thus, small molecules have
been designed by pharmaceutical researchers and companies,
stimulated by the recent advancements of structural data on several
KLKs (Table 4). Due to the requiredmimicking of a natural active site
binding molecule, such inhibitory compounds often contain amino
acid derived groups, as the b-lactam derived 2-azetidinone with
a Tyr side chain that inhibited KLK3 with an IC50 of 226 nM andwas
apparently designed obeying the “rule of ﬁve” [275]. In particular,
for KLK3 heterocyclic compounds in a structureeactivity relation-
ship approach reached an IC50 of 300 nM [276].
The pharmaceutical relevance of KLK7 inhibitors is evidenced
by patents for a small molecule KLK7 inhibitor [277] (“Use of
cyclic depsipeptides to inhibit Kallikrein 7”, WO2009024528 (A1).
Novartis) that was analyzed by X-ray crystallography with the
purpose of applying such compounds in treatments for human skin
diseases, in particular atopic dermatitis, psoriasis or Netherton’s
syndrome [278].
4.2. Peptide-based inhibitors of KLKs
Already in 1981, a very efﬁcient inhibitor of KLK1was generated,
which contained a P3-D-Phe residue and reached an IC50 of 800 nM
[279]. Potent analgesic and anti-inﬂammatory peptidic compounds
that contain the non-natural amino acid L-4-aminomethyl-
phenylalanine inhibited KLK1 with a Ki of 1.2 mM [280]. Another
synthetic peptide-based inhibitor speciﬁc for KLK1 (FE999024) wased and the single dots putative roles in the respective disease, also in cases when the
Teeth Lung Brain
Amylo-genesis
Imperfecta
Asthma Multiple
sclerosis
Alzheimer Epilepsy
CC
[318]
CC
[58,59]
C
[70]
C
[320]
C
[76]
C
[77]
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[281]. Pure peptide based-inhibitors of KLK2 for targeting prostate
cancer were found by screening phage display peptide libraries,
resulting in 10e11 amino acid long linear peptides with IC50 values
reaching 1.4 mM [282]. This basic approach was extended and
improved by introducing cyclic peptides as efﬁcient KLK2 inhibitors
[283,284]. Also, so-called azapeptides that contain one N-atom
instead of a Ca, e.g. tBOC-Ser-Phe-aza-Tyr-phenoxy, resulted in
KLK3 inhibition with a Ki of 500 nM [285]. Non-hydrolyzable
boronic acid inhibitors, such as carbobenzyloxy-Ser-Ser-Lys-P1-
Leu-(boro)-P10-Leu, turned out to be much more speciﬁc for the
chymotryptic KLK3 with a Ki of 65 nM than for chymotrypsin
itself (Ki ¼ 3.9 mM) [286]. This inhibitor type was improved by
introducing the non-natural amino acid nor-leucine (Nle) into
CBZ-Ser-Ser-Gln-Nle-(boro)-Leu to result for KLK3 in a Ki of 25 nM,
which could be employed as imaging agent for prostate cancer by
attachment of a metal chelating group to the compound [287].
A detailed overview of peptide based and other small molecule
inhibitors of KLK3 by LeBeau and coworkers is focussed on their
usage in selective imaging and in targetted treatment of prostate
cancer [288]. Recently, the naturally occurring 14 residue long cyclic
sunﬂower trypsin inhibitor (SFTI of the Bowman-Birk family) was
re-engineered by a combination of molecular modeling and sparse
matrix substrate screening, to block the proteolytic activity of KLK4
(Ki¼ 3.6 nM) and potentially block stimulation of PAR activity [289].
Fully synthetic domain 6 of LEKTI, which was generated by frag-
ment condensation of residues 1e22 and 23e68, inhibited KLK5
with an IC50 of 120 nM, which is slightly lower than measured for
the recombinantly produced peptide (IC50 ¼ 135 nM) [290].
4.3. Endogenous human inhibitors serve as scaffold
for therapeutic agents
After determination of the substrate speciﬁcity of KLK2 [106],
selected substrates sequences were transplanted into the reactive
site loop of a1-antichymotrypsin (ACT), yielding a highly speciﬁc
KLK2 inhibitor with high reactivity, which could be a useful tool to
detect and target prostate cancer progression [291]. In a related
approach, based on determination of the KLK14 speciﬁcity by phage
display [104], selected substrates were incorporated as modiﬁed
reactive site loop into the scaffold of serpins a1-antitrypsin (AAT) or
ACT, which formed covalent complexes with KLK14, especially the
engineered ACT inhibitors [292].
4.4. Engineered antibodies inhibit the proteolytic activity of KLKs
The antibody scaffold for the design of novel protease inhibitors
offers some advantages over common inhibitors that bind in
a substrate-likemanner, since antibodies can in addition to binding of
the often conserved protease active sites exploit binding to more
variable individual exosites on the protease surface, which may
enhance the selectivity of inhibition extraordinarily [293]. In case of
KLK1 an engineered antibody bound speciﬁcally to the active site of
the tryptic protease, resulting in inhibition of the peptidase activity
with an inhibition constant around 130pM, paving theway for a novel
cure of asthma [294]. Also, a monoclonal antibody against KLK4 was
capable of reducing its activity in vitro, although this engineered
molecule needs further optimization [178]. Similarly, for KLK13,which
is overexpressed in ovarian cancer patients, a monoclonal antibody
inhibited its activity, leading possibly to a therapeutic application [14].
5. Conclusions and outlook
Kallikrein-related peptidases are a family of serine proteases
that has diversiﬁed through evolution for physiological tasks thathave arisen with the special developments of mammals compared
with their ancestors. These novel functions comprise proteolytic
processes in fertilization, desquamation, or a sophisticated
neuronal plasticity. However, the activity of KLK proteases requires
tight regulation by modulators, as activating or attenuating ions or
reversible and irreversible proteinaceous inhibitors. In some cases,
the failure of endogenous inhibitory systems in humans leads to
excessive activity of KLKs with pathophysiological consequences.
Apart from the current scientiﬁc and pharmacological key
interest, KLK functions may go far beyond the normal protease
activity, as seen in some impressive examples depicting the regula-
tory potential of KLKs. First, inmouse nerve growth factor 7S, the two
active mouse KLK b3 proteases or g subunits are inhibited by Zn2þ
mediated complex formation with an inactive b subunit and two
inactive a subunits (KLK homologs), whereby the g active sites are
shielded from potential substrates [295e297]. Secondly, the myste-
rious localization of KLK4 in the cytoplasm as full length protein
and in the nucleus of transfected prostate cancer cells (PC-3) as
N-terminally truncated KLK4-205 awaits new functional models for
KLKs, in particular due to a likely involvement in cancer [298,299].
Built according to the rather simple scaffold of (chymo)trypsin-like
serine proteases, the kallikrein-related peptidases represent exciting
biomolecules with astonishing variations in their structure, function,
and physiological regulation. Eventually, our increasing knowledge
of the underlying mechanisms of KLK activity control, will help to
design very speciﬁc compounds directed to individual KLKs in order
to cure diseases in which they play an important role.
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